Indigo Medical's laser cleared for general surgery:
This article was originally published in Clinica
Indigo Medical's portable 830 diode laser system has been cleared by the US FDA for use in general surgery and urological and gastroenterological procedures. Six-month follow-up of 100 patients treated with the laser for benign prostatic hyperplasia is under way in preparation for 510(k) clearance. The system, which is CE-marked, is already marketed for BPH treatment outside the US through Indigo's German and Hong Kong subsidiaries (see Clinica No 672, p 18).
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.